408 Dupilumab reduces biomarkers indicative of type 2 inflammation in children aged ≥ 6 months to 5 years with moderate-to-severe atopic dermatitis

Dupilumab was previously shown to reduce thymus and activation-regulated chemokine (TARC/CCL17) total IgE levels in multiple type 2 inflammatory diseases, including atopic dermatitis (AD). Here, we assess the effects of dupilumab treatment on these biomarkers inflammation children aged 6 months – 5 years with moderate-to-severe AD. In LIBERTY AD PRE-SCHOOL (NCT03346434 part B), a phase 3, double-blind trial, ≥ inadequately controlled topical therapies were randomized 1:1 subcutaneous (200 mg if baseline weight < 15 kg, 300 30 kg) or placebo every 4 weeks for 16 weeks. All patients received standardized low-potency corticosteroids. Serum biomarker analysis collected at baseline, Week 4, 16. Baseline median serum TARC dupilumab/placebo groups (n = 83/79) 3,295/3,190 pg/mL 2,190/3,240 kU/L, respectively. After treatment, % change from –83.1%/–12.8% –71.2%/28.1% (both P<0.0001). Similar reductions observed dupilumab- vs placebo-treated all tested allergen-specific IgEs (peanut, egg white, soybean, Dermatophagoides farinae pteronyssinus). significantly reduced controls, reflecting reduction systemic inflammation.